Status:
COMPLETED
Memory Functioning and Antidepressant Treatment
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
GlaxoSmithKline
H. Lundbeck A/S
Conditions:
Depression
Major Depressive Disorder
Eligibility:
All Genders
18-50 years
Phase:
PHASE3
Brief Summary
Major Depressive Disorder (MDD) is a serious illness associated with considerable morbidity, risk of suicide and adverse social consequences (Montgomery et al., 1994a). Cognitive impairment is one of ...
Detailed Description
Purpose of the Present Study: The purpose of the present study is to comprehensively evaluate memory functioning of MDD patients before and after 8 weeks of antidepressant treatment with bupropion-XL...
Eligibility Criteria
Inclusion
- Males and Females
- Age: 18-50
- Recurrent Major Depressive Disorder; current Major Depressive Episode with at least one prior episode
- HAM-D \>16
- Able to give written informed consent
- Agree to use a reliable means of birth control during the study, as determined by the investigator (females of child-bearing potential only)
Exclusion
- History of head injury or loss of consciousness for longer than 30 minutes
- Presence of primary anxiety disorder, bipolar I or II disorder, or psychotic disorders
- Presence of anorexia nervosa or bulimia nervosa
- Presence or history of epilepsy or other seizure disorders
- Presence of significant Axis II disorder based on investigator judgment
- Presence of significant unstable medical condition
- Presence or past history of ADHD or significant learning disability
- ECTs (unilateral) within the past 12 months or bilateral ECT (ever)
- More than 2 failed adequate antidepressant treatments in the current episode
- Pregnant or breast-feeding females
- Have received treatment within the last 30 days with an investigational drug
- Prior non-response to either bupropion-XL or escitalopram
- Current treatment with Zyban (bupropion hydrochloride)
- Antidepressant treatment within the last week (within the last 3 weeks fluoxetine)
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00296933
Start Date
December 1 2005
Last Update
February 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2C4